Table 2.
Three studies of the UNOS registry evaluating the ability of AFP to predict prognosis after LT.
| Author (Reference) | Dates | Sample Size | Categories | Overall Survival (%) at 4 years |
|---|---|---|---|---|
| Toso C | 2002–2008 | HCC = 6,478 | TTV≤115 AND AFP≤400 | 60 |
| (Hepatology 2009) | TTV>115 = 18 | |||
| AFP>400 = 465 | TTV>115 OR AFP>400 | 35 | ||
| Mailey B | 2003–2008 | HCC = 2253 | AFP <20 (n=1210) | 76 |
| (Arch Surg 2011) | ||||
| AFP 20–399 | 65 | |||
| (n=805) | ||||
| AFP >400 | 57 | |||
| (n=238) | ||||
| Berry K | 2002–2011 | No HCC = 31,789 HCC with eMELD = 10,282 HCC with no eMELD = 3,196 | AFP <15 (n=4783) | 78 |
| (Liver Transpl 2013) | ||||
| AFP 16–65 (n=1998) | 70 | |||
| AFP 66–320 (n=1160) | 65 | |||
| AFP >320 (n=718) | 57 | |||
AFP = alpha-fetoprotein; eMELD = exemption Model for Endstage Liver Disease points; HCC = hepatocellular carcinoma; TTV = total tumour volume.